At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 109 enrolled
Drug / intervention
entecavirdrug
Likely dose
entecavir 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection
In Brief
A Phase 3 clinical trial evaluating entecavir for Hepatitis B, Chronic. Completed, enrolled 109 participants across 32 sites in 9 countries.
Detailed Summary
The purpose of this clinical research study is to learn if the study drug entecavir will prevent the recurrence of hepatitis B virus (HBV) in participants who receive an orthotopic liver transplant (OLT) due to HBV infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesArgentina, Australia, Brazil, France, Italy, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2006
Enrollment StartApr 2007
Primary CompletionMar 2011
TodayJul 2026
First PostedNov 2, 2006
Enrollment StartApr 1, 2007
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 19.7 years ago
Interventions
entecavirdrug
Tablets, Oral, 1 mg, once daily, up to 72 weeks